Viking Global reports 4.995% BridgeBio stake

Viking Global Investors and affiliated entities filed Amendment No. 12 reporting beneficial ownership of 9,792,219 shares of BridgeBio Pharma, Inc. common stock, representing approximately 4.9951% of the outstanding shares.

Rhea-AI Filing Summary

Viking Global Investors and affiliated entities filed Amendment No. 12 reporting beneficial ownership of 9,792,219 shares of BridgeBio Pharma, Inc. common stock, representing approximately 4.9951% of the outstanding shares. The percentage is rounded to 5% on the cover pages, based on 196,036,786 shares outstanding as of May 31, 2026. The stake is held through a complex Viking Global Opportunities fund structure, with shared voting and dispositive power over all reported shares. As of July 9, 2026, the reporting persons state they ceased to be beneficial owners of more than 5% of BridgeBio’s common stock. Recent trading activity over the prior 60 days is listed in Exhibit 99.14.

Key Figures

Beneficially owned shares: 9,792,219 shares Ownership percentage (exact): 4.9951% Ownership percentage (rounded): 5% +3 more

6 metrics

Beneficially owned shares 9,792,219 shares Shares of BridgeBio Pharma common stock beneficially owned by each reporting person

Ownership percentage (exact) 4.9951% Approximate percentage of BridgeBio common stock beneficially owned by each reporting person

Ownership percentage (rounded) 5% Percent of class shown in Row 13, rounded per Rule 13d-101 instructions

Shares outstanding baseline 196,036,786 shares BridgeBio common shares outstanding as of May 31, 2026, used for ownership calculations

Ceased >5% holder date July 9, 2026 Date on which the reporting persons ceased to be beneficial owners of more than 5% of the class

Shared voting power 9,792,219 shares Number of BridgeBio shares over which the reporting persons have shared voting power

Key Terms

beneficial ownership, shared voting power, shared dispositive power, Schedule of Transactions, +1 more

5 terms

beneficial ownership regulatory

"Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

shared voting power financial

"Shared Voting Power 9,792,219.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 9,792,219.00"

Schedule of Transactions regulatory

"Exhibit 99.14 - Schedule of Transactions"

percent of class financial

"Percent of class represented by amount in Row (11) 5 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

What percentage of BridgeBio Pharma (BBIO) does Viking Global now report owning?

Viking Global and affiliated entities report beneficial ownership of approximately 4.9951% of BridgeBio Pharma’s common stock, rounded to 5% on the cover pages, based on 196,036,786 shares outstanding as of May 31, 2026.

How many BridgeBio Pharma (BBIO) shares are beneficially owned by Viking Global?

Viking Global and its related entities report beneficial ownership of 9,792,219 BridgeBio Pharma common shares, with shared voting and dispositive power over all of these shares through their fund structure.

When did Viking Global fall below 5% ownership in BridgeBio Pharma (BBIO)?

The reporting group states that as of July 9, 2026 they ceased to be beneficial owners of more than 5% of BridgeBio Pharma’s common stock, marking a threshold change in their reportable stake.

What share count did Viking Global use to calculate its BridgeBio (BBIO) ownership percentage?

The ownership percentage was calculated using 196,036,786 BridgeBio common shares outstanding as of May 31, 2026, a figure taken from an exhibit to BridgeBio’s Form 8-K filed on July 2, 2026.

Does Viking Global have sole or shared voting power over its BridgeBio (BBIO) shares?

The reporting persons indicate 0 shares with sole voting power and 9,792,219 shares with shared voting and dispositive power, reflecting control exercised collectively through Viking Global Opportunities entities.

Are there recent BridgeBio (BBIO) transactions by Viking Global disclosed in this amendment?

The filers state that, other than the transactions listed in Exhibit 99.14, they have not effected any BridgeBio common stock trades in the past 60 days; the exhibit provides the detailed schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/10/2026 - 07:03 PM Accepted by SEC EDGAR 07/10/2026 - 07:03 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 12)

BridgeBio Pharma, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

10806X102

(CUSIP Number)

Matthew Bloom
General Counsel, 600 Washington Boulevard, Floor 11
Stamford, CT, 06901
(212) 672-7059

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/09/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 10806X102

1

Name of reporting person

VIKING GLOBAL INVESTORS LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,792,219.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,792,219.00

11

Aggregate amount beneficially owned by each reporting person

9,792,219.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Common Stock, par value $0.001 per share (the "Common Stock"), of BridgeBio Pharma, Inc. (the "Issuer"). The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101. All share percentage calculations in this Amendment No. 12 to the Schedule 13D are based on 196,036,786 shares of Common Stock of the Issuer outstanding as of May 31, 2026, as reported in exhibit 10.1 to the Issuer's current report on Form 8-K filed with the Securities and Exchange Commission (the "Commission") on July 2, 2026.

SCHEDULE 13D

CUSIP Number(s): 10806X102

1

Name of reporting person

Viking Global Opportunities Parent GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,792,219.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,792,219.00

11

Aggregate amount beneficially owned by each reporting person

9,792,219.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Issuer's Common Stock. The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101.

SCHEDULE 13D

CUSIP Number(s): 10806X102

1

Name of reporting person

Viking Global Opportunities GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,792,219.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,792,219.00

11

Aggregate amount beneficially owned by each reporting person

9,792,219.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Issuer's Common Stock. The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101.

SCHEDULE 13D

CUSIP Number(s): 10806X102

1

Name of reporting person

Viking Global Opportunities Portfolio GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,792,219.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,792,219.00

11

Aggregate amount beneficially owned by each reporting person

9,792,219.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Issuer's Common Stock. The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101.

SCHEDULE 13D

CUSIP Number(s): 10806X102

1

Name of reporting person

Viking Global Opportunities Illiquid Investments Sub-Master LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,792,219.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,792,219.00

11

Aggregate amount beneficially owned by each reporting person

9,792,219.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Issuer's Common Stock. The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101.

SCHEDULE 13D

CUSIP Number(s): 10806X102

1

Name of reporting person

HALVORSEN OLE ANDREAS

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NORWAY

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,792,219.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,792,219.00

11

Aggregate amount beneficially owned by each reporting person

9,792,219.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Issuer's Common Stock. The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101.

SCHEDULE 13D

CUSIP Number(s): 10806X102

1

Name of reporting person

Shabet Rose Sharon

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 9,792,219.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 9,792,219.00

11

Aggregate amount beneficially owned by each reporting person

9,792,219.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Issuer's Common Stock. The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: BridgeBio Pharma, Inc.
(c)	Address of Issuer's Principal Executive Offices: 3160 Porter Drive, Suite 250, Palo Alto, CALIFORNIA , 94304.
Item 1 Comment: Pursuant to Rule 13d-2 under the Securities Exchange Act of 1934, as amended, this Amendment No. 12 to the Schedule 13D ("Amendment No. 12") amends certain items of the Schedule 13D filed with the Commission on July 8, 2019, as amended and supplemented by Amendment No. 1 filed with the Commission on July 19, 2023, Amendment No. 2 filed with the Commission on November 22, 2023, Amendment No. 3 filed with the Commission on August 20, 2024, Amendment No. 4 filed with the Commission on November 6, 2024, Amendment No. 5 filed with the Commission on January 31, 2025, Amendment No. 6 filed with the Commission on March 12, 2025, Amendment No. 7 filed with the Commission on July 1, 2025, Amendment No. 8 filed with the Commission on August 14, 2025, Amendment No. 9 filed with the Commission on November 14, 2025, Amendment No. 10 filed with the Commission on February 17, 2026 and Amendment No. 11 filed with the Commission on April 2, 2026 (collectively, the "Schedule 13D") relating to the Common Stock, par value $0.001 per share (the "Common Stock") of BridgeBio Pharma, Inc., a Delaware corporation (the "Issuer"). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.
Item 4.	Purpose of Transaction
	Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The response to Item 5(c) of this Amendment No. 12 is incorporated by reference herein.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: The information contained on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 are hereby incorporated herein by reference. Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Issuer's Common Stock. The percent of class reported in Row 13 of each Reporting Person's cover sheet has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101. Such percentage was calculated for each Reporting Person based on 196,036,786 shares of Common Stock outstanding as of May 31, 2026, as reported in exhibit 10.1 to the Issuer's current report on Form 8-K filed with the Commission on July 2, 2026. Opportunities Fund has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to Opportunities Fund. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through Opportunities Fund. VGI provides managerial services to Opportunities Fund. VGI has the power to direct the voting and disposition of the shares of Common Stock directly held by Opportunities Fund. Accordingly, VGI may be deemed to have beneficial ownership over any shares of Common Stock directly owned by Opportunities Fund. Opportunities Portfolio GP serves as the general partner of Opportunities Fund and has the power to direct the voting and disposition of the shares of Common Stock directly held by Opportunities Fund. Accordingly, Opportunities Portfolio GP may be deemed to have beneficial ownership over any shares of Common Stock directly owned by Opportunities Fund. Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the power to direct the voting and disposition of the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by Opportunities Fund. Accordingly, Opportunities GP may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by Opportunities Portfolio GP, consisting of any shares of Common Stock directly owned by Opportunities Fund. Opportunities Parent serves as the sole member of Opportunities GP, which has the power to direct the voting and disposition of the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by Opportunities Fund. Accordingly, Opportunities Parent may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by Opportunities GP, consisting of any shares of Common Stock directly owned by Opportunities Fund. Mr. Halvorsen and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (the general partner of VGI) and Opportunities Parent, have shared authority to direct the voting and disposition of the shares of Common Stock beneficially owned by VGI and Opportunities Parent. Accordingly, each of Mr. Halvorsen and Ms. Shabet may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by VGI and Opportunities Parent. Except as disclosed in this Amendment No. 12, none of the Reporting Persons beneficially owns any shares of Common Stock or has the right to acquire any shares of Common Stock. Except as disclosed in this Amendment No. 12, none of the Reporting Persons presently has the power to vote or to direct the voting or to dispose or direct the disposition of any shares of Common Stock that such Reporting Person may be deemed to beneficially own.
(b)	Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows: The information contained on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 are hereby incorporated herein by reference.
(c)	Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows: Except for the transactions listed in Exhibit 99.14 of this Amendment No. 12, the Reporting Persons have not effected any transactions in the Common Stock during the past 60 days.
(e)	As of July 9, 2026, the Reporting Persons ceased to be beneficial owners of more than 5% of the shares of Common Stock.
Item 7.	Material to be Filed as Exhibits.
	Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit 99.14 - Schedule of Transactions

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

VIKING GLOBAL INVESTORS LP

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)
Date:	07/10/2026

Viking Global Opportunities Parent GP LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)
Date:	07/10/2026

Viking Global Opportunities GP LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)
Date:	07/10/2026

Viking Global Opportunities Portfolio GP LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)
Date:	07/10/2026

Viking Global Opportunities Illiquid Investments Sub-Master LP

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)
Date:	07/10/2026

HALVORSEN OLE ANDREAS

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of HALVORSEN OLE ANDREAS (1)
Date:	07/10/2026

Shabet Rose Sharon

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Shabet Rose Sharon (2)
Date:	07/10/2026

Comments accompanying signature:

(1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).